Clinical Outcomes of Patients with Multiple Myeloma Presenting with Renal Failure.

Introduction

Multiple myeloma is characterized by the neoplastic proliferation of clonal plasma cells, which produce excess monoclonal immunoglobulins, light chains, or both, often resulting in organ damage. It is a disease with a relapsing and remitting course. Renal dysfunction at diagnosis presents a great challenge in management and is a factor leading to inferior outcomes. 1

Managing patients with multiple myeloma and renal failure requires a multidisciplinary approach involving disease-directed therapy alongside renal replacement therapy in cases of severe renal dysfunction. Bortezomib-based regimens are the most commonly used first-line regimes in the treatment of multiple myeloma. Owing to ease of accessibility and renal safety profile, bortezomib remains the cornerstone of management of these patients in India. In this study, we present our experience of bortezomib-based triplet regimes in patients with multiple myeloma presenting with renal dysfunction at baseline.

Methods

The aim of this study was to study the clinical outcome of patients with multiple myeloma with renal failure at presentation who were treated with bortezomib-based triplet therapy. This was a prospective observational study conducted at a tertiary hospital in North India from October 1, 2022 to March 31, 2024. Approval from the institutional ethics committee was obtained prior to starting enrolment. Consecutive patients with newly diagnosed multiple myeloma presenting with serum creatinine of more than or equal to 2 mg/dL were included in the study. Those patients with preexisting chronic kidney disease prior to the diagnosis of multiple myeloma and those who died within 2 weeks of diagnosis were excluded. All patients were treated with bortezomib-based triplet therapy (at the discretion of the treating physician). Response assessment was done at completion of 6 months from diagnosis. The International Myeloma Working Group criteria were followed for diagnosis and response assessment. 2 Only patients who had completed 6 months of follow-up were included in the final analysis. Data collection and analysis were done by Microsoft Excel and SPSS.

Results

Thirty patients were enrolled during the study duration. Baseline demographic, clinical, and risk stratification data are presented in Table 1 . The median age was 60 years, and the male:female ratio was 2:1. Sixteen patients (53.3%) had baseline estimated glomerular filtration rate (eGFR) less than 15 mL/min/1.73 m 2 . Six patients (20%) were dialysis-dependent on presentation. Majority of patients had anemia and lytic bony lesions at diagnosis. Half of the patients were International Staging System (ISS) stage III. All patients received bortezomib (1.3 mg/m 2 )- and dexamethasone (40 mg weekly)-based treatment regimens; 21 patients (70%) received cyclophosphamide (300 mg/m 2 weekly), 6 patients (20%) received thalidomide (100 mg once a day), and 3 patients (10%) received lenalidomide (10 mg once a day for 3 out of 4 weeks) as the third agent. Renal response analysis was done every month as per the criteria for renal response to antimyeloma therapy, out of 30 patients 27 patients achieved some kind of renal response, the minimum being a minor response.

The final response assessment was done at a follow-up of 6 months ( Table 2 ). Half of the patients achieved a renal complete response (CR); the highest being in the lenalidomide group (83.3%). Patients with eGFR < 15 mL/min/m 2 at presentation fared poorly versus those with eGFR > 15 mL/min/m 2 (combined renal CR and partial response [PR] rates 36% vs. 92%). Patients who were dialysis-dependent at baseline had poorer renal responses as compared with those who were dialysis-independent (cumulative renal CR and PR, 32% vs. 80%). Out of six patients who were initially dialysis-dependent, 4 (66.6%) became dialysis-independent after treatment. There were no differences in renal responses among those with difference between involved minus uninvolved serum free light chains (dFLC) greater than or less than 1,000 mg/L at baseline. Renal response as per ISS staging; light chain biochemical response at 6 months were CR (16%), very good PR (VGPR) (26%), PR (23%), stable disease (26%), and progression (9%). At 2 months after the start of treatment, 18 patients (60%) achieved biochemical CR or VGPR; renal CR in this group of patients was 72% as against 16% in those who were not in CR or VGPR at 2 months.

Discussion

Renal dysfunction is seen in almost half of all patients with multiple myeloma at presentation. 3 It can be related to the circulating paraprotein or unrelated (hypercalcemia, nonsteroidal anti-inflammatory drug use, dehydration, or infection). 3 Most of the paraprotein-related injury is due to myeloma cast nephropathy, characterized by deposition of a cast consisting of monoclonal free light chain along with Tamm–Horsfall protein in the distal tubules. Other pathologies seen are light chain amyloidosis and light chain deposition disease. Renal dysfunction is a poor prognostic marker and is associated with inferior overall survival, particularly if it does not improve with treatment. 4 The presence of dialysis dependence is also an adverse prognostic factor in these patients. 5

Novel agent-based treatment is favored over conventional chemotherapeutic approaches and that is true even in the setting of renal dysfunction. 6 Bortezomib, cyclophosphamide, thalidomide, and dexamethasone can be used without any dose modifications, while lenalidomide may be used in reduced doses. Plasma exchange, high cutoff dialysis, and urine alkalization have not been observed to offer any conclusive benefit and were not used in any of our patients.

Bortezomib-based regimens are the mainstay of treatment of multiple myeloma with renal impairment. 7 We observed renal CR and PR rates of 50 and 16.6%, respectively, and dialysis independence rate of 66.6% with bortezomib-based triplet therapy. In patients with severe renal dysfunction, bortezomib-based triplets have shown renal CR and PR rates of 35 and 12%, respectively, and dialysis discontinuation rates of 57%. 8 In a study from India, Pandey et al showed renal CR and PR rates of 25 and 40%, respectively, in dialysis-dependent patients treated with bortezomib and dexamethasone doublet. 9

We observed that severity of renal dysfunction at baseline correlated with poor renal outcomes. 10 11 12 13 14 We also observed that patients who attained a rapid biochemical response fared better. This is consistent with other studies using bortezomib-based regimens. Since renal injury is directly related to the circulating paraprotein, rapid clearance of the same with effective antimyeloma therapy provides the best renal outcomes.

In conclusion, we would like to state that treatment of multiple myeloma with Bortezomib + Dexamethasone-based regimes has shown rapid and significant renal response and has also increased the probability of these patients becoming dialysis-independent, further preserving their quality of life.

Conflict of Interest None declared.

References

1 Bladé J Fernández-Llama P Bosch F Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution Arch Intern Med 1998 158 17 1889 1893 9759684 10.1001/archinte.158.17.1889

2 Rajkumar S V Dimopoulos M A Palumbo A International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Lancet Oncol 2014 15 12 e538 e548 25439696 10.1016/S1470-2045(14)70442-5

3 Yadav P Cook M Cockwell P Current trends of renal impairment in multiple myeloma Kidney Dis (Basel) 2016 1 04 241 257 27536684 10.1159/000442511 PMC4934811

4 Mohyuddin G R Hampton J Aziz M A systematic review and network meta-analysis of randomized data on efficacy of novel therapy combinations in patients with lenalidomide-refractory multiple myeloma Clin Lymphoma Myeloma Leuk 2021 21 07 489 496 33962898 10.1016/j.clml.2021.03.006

5 Haynes R J Read S Collins G P Darby S C Winearls C G Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre Nephrol Dial Transplant 2010 25 02 419 426 19767634 10.1093/ndt/gfp488

6 International Myeloma Working Group Dimopoulos M A Merlini G Bridoux F Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group Lancet Oncol 2023 24 07 e293 e311 37414019 10.1016/S1470-2045(23)00223-1

7 Zhu W Chen W Bortezomib-based treatment for multiple myeloma patients with renal impairment: a systematic review and meta-analysis of observational studies Medicine (Baltimore) 2016 95 46 e5202 27861343 10.1097/MD.0000000000005202 PMC5120900

8 Dimopoulos M A Sonneveld P Leung N International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment J Clin Oncol 2016 34 13 1544 1557 26976420 10.1200/JCO.2015.65.0044

9 Beneficial effect of complete response and type of therapy in multiple myeloma J Clin Oncol 2013 13 15 8541 8541

10 Hutchison C A Bradwell A R Cook M Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis Clin J Am Soc Nephrol 2009 4 04 745 754 19339414 10.2215/CJN.04590908 PMC2666427

11 Wirk B Renal failure in multiple myeloma: a medical emergency Bone Marrow Transplant 2011 46 06 771 783 21339749 10.1038/bmt.2011.8

12 Torra R Bladé J Cases A Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases Br J Haematol 1995 91 04 854 859 8547129 10.1111/j.1365-2141.1995.tb05400.x

13 Nozza A Siracusano L Armando S Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function Clin Ther 2006 28 06 953 959 16860177 10.1016/j.clinthera.2006.06.009

14 Roussou M Kastritis E Migkou M Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens Leuk Lymphoma 2008 49 05 890 895 18464107 10.1080/10428190801930506